2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

Journal of Hypertension

Volumn 21, Issue 6, 2003, Pages 1011-1053

  Zanchetti, Alberto ^a  

^a Ctro Fisiol Clinica e Ipertensione   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMPHETAMINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CANDESARTAN; CHLORTALIDONE; COCAINE; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROPOIETIN; FOSINOPRIL; GLUCOSE; GLYCYRRHIZA EXTRACT; INDAPAMIDE; LACIDIPINE; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; STEROID; UNINDEXED DRUG;

AMBULATORY MONITORING; ANAMNESIS; AORTA COARCTATION; ARTERY COMPLIANCE; AUTOMATION; BLOOD PRESSURE MONITORING; CARDIOLOGY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; CUSHING SYNDROME; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HEALTH CARE SYSTEM; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HOME CARE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY PARENCHYMA; LABORATORY TEST; LIFESTYLE; MEDICAL SOCIETY; METABOLIC DISORDER; MICROALBUMINURIA; OBESITY; OSCILLOMETRY; PAPILLEDEMA; PERSONALITY; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PULSE PRESSURE; RANDOMIZATION; RENOVASCULAR HYPERTENSION; RETINA ARTERY OCCLUSION; RETINA HEMORRHAGE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; ULTRASOUND; WHITE COAT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; EUROPE; HUMANS; HYPERTENSION; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 0037527647     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200306000-00001     Document Type: Review

References (342)

1. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11:905-918. GL
2. Guidelines Sub-Committee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151-183. GL
3. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15:1300-1331. GL
4. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19:1434-1503. GL
5. Collins R, Peto R, MacMahon S, Herbert P, Fieback NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-839. MA
6. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774. MA
7. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913. MA
8. Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001; 10:190-192. RV
9. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control. Results from the Health Survey for England 1998. Hypertension 2001; 38:827-832.
10. O'Rourke MF. From theory into practice. Arterial hemodynamics in clinical hypertension. J Hypertens 2002; 20:1901-1915. OS
11. Millar JA, Lever AF, Burke A. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999; 17:1065-1072. OS
12. Franklin S, Khan SA, Wong DA, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100:354-360. OS
13. Franklin S, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245-1249. OS
14. Benetos A, Zureik M, Morcet J, Thomas F, Bean K, Safar M, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000; 35:673-680. OS
15. SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264. RT
16. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764. RT
17. Evans JG, Rose G. Hypertension. Br Med Bull 1971; 27:37-42. RV
18. Zanchetti A, Mancia G. Editor's Corner. New year, new challenges. J Hypertens 2003; 21:1-2.
19. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46:1594-1600. OS
20. Zanchetti A. The hypertensive patient with multiple risk factors: is treatment really so difficult? Am J Hypertens 1997; 10:223S-229S.
21. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823-2828. OS
22. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 2000; 320:709-710. OS
23. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-362. OS
24. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81:40-46. OS
25. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21:365-370. OS
26. Menotti A, Lanti M, Puddu PE, Carratelli L, Mancini M, Motolese M, et al. An Italian chart for cardiovascular risk prediction. Its scientific basis. Ann Ital Med Int 2001; 16:240-251. OS
27. Rodes A, Sans S, Balana LL, Paluzie G, Aguilera R, Balaguer-Vintro I. Recruitment methods and differences in early, late and non-respondents in the first MONICA-Catalonia population survey. Rev Epidemiol Santé Publique 1990; 38:447-453. OS
28. Schroll M, Jorgensen T, Ingerslev J. The Glostrup Population Studies, 1964-1992. Dan Med Bull 1992; 39:204-207. OS
29. Keil U, Liese AD, Hense HW, Filipiak B, Doring A, Stieber J, Lowel H. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J 1998; 19:1197-1207. OS
30. Tunstall-Pedoe H, Woodward M, Tavendale R, Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. BMJ 1997; 315:722-729. OS
31. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P. Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol 2000; 29:49-56. OS
32. Pocock SJ, Cormack VMc, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001; 323:75-81. OS
33. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. on behalf of the SCORE project group. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 (in press). OS
34. Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens 1996; 14:683-689.
35. Zanchetti A. Antihypertensive therapy. How to evaluate the benefits. Am J Cardiol 1997; 79:3-8.
36. Franklin SS, Wong ND. Cardiovascular risk evaluation: an inexact science. J Hypertens 2002; 20:2127-2130.
37. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106:286-288.
38. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikanen R, Bulpitt CJ, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340:677-684. RT
39. Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19:1149-1159. OS
40. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12:218-225. RT
41. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369. RV
42. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397. OS
43. Cuspidi C, Macca G, Salerno M, Michev L, Fusi V, Severgnini B, et al. Evaluation of target organ damage in arterial hypertension: which role for qualitative funduscopic examination? Ital Heart J 2001; 2:702-706. OS
44. Yikona JI, Wallis EJ, Ramsay LE, Jackson PR, Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. J Hypertens 2002; 20:2173-2182. OS
45. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20:1307-1314. OS
46. Chalmers JP, Zanchetti A (co-chairmen). Hypertension control Report of a WHO expert committee. Geneva: World Health Organization; 1996. GL
47. Mancia G, Parati G, Di Rienzo M, Zanchetti A. Blood pressure variability. In: Zanchetti A, Mancia G (editors): Handbook of hypertension: pathophysiology of hypertension. Amsterdam: Elsevier Science; 1997, pp. 117-169. RV
48. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al. on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821-848. GL
49. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531-536. GL
50. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000; 36:894-900. RV
51. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment induced regression of left ventricular hypertrophy. Circulation 1997; 95:1464-1470. OS
52. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension 1997; 29:22-29. OS
53. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81:528-536. OS
54. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001; 19:1981-1989. OS
55. Imai Y, Ohkubo T, Sakuma M, Tsuji I, Satoh H, Nagai K, et al. Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: a prospective observation in a cohort from Ohasama, Northern Japan. Blood Press Monit 1996; 1:251-254. OS
56. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16:971-975. OS
57. Staessen JA, Thijs L, Fagard R, O'Brien E, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282:539-546. OS
58. Robinson TG, Dawson SN, Ahmed U, Manktelow B, Fortherby MD, Potter JF. Twenty-four hour systolic blood pressure predicts long-term mortality following acute stroke. J Hypertens 2001; 19:2127-2134. OS
59. Parati G, Pomidossi G, Casadei V, Mancia G. Lack of alerting reactions and pressor responses to intermittent cuff inflations during non-invasive blood pressure monitoring. Hypertension 1985; 7:597-601.
60. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995; 8:311-315.
61. Coats AJS, Radaelli A, Clark SJ, Conway J, Sleight P. The influence of ambulatory blood pressure monitoring. The design and interpretation of trials in hypertension. J Hypertension 1992; 10:385-391.
62. Mancia G, Ulian L, Parati G, Trazzi S. Increase in blood pressure reproducibility by repeated semi-automatic blood pressure measurements in the clinic environment. J Hypertens 1994; 12:469-473.
63. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997; 10:1201-1207. OS
64. Staessen J, Fagard RH, Lijnen PJ, Van Hoof R, Amery AK. Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. Am J Cardiol 1991; 67:723-727. MA
65. Mancia G, Sega R, Bravi C, De Vito G, Valagussa F, Cesana G, et al. Ambulatory blood pressure normality: results from the PAMELA Study. J Hypertens 1995; 13:1377-1390. OS
66. Ohkubo T, Imai Y, Tsuji I, Nagai K, Ito S, Satoh H, Hisamichi S. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. Hypertension 1998; 32:255-259. OS
67. Sakuma M, Imai Y, Nagai K, Watanabe N, Sakuma H, Minami N, et al. Reproducibility of home blood pressure measurements over a 1-year period. Am J Hypertens 1997; 10:798-803. OS
68. Zarnke KB, Feagan BG, Mahon JL, Feldman RD. A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. Am J Hypertens 1997; 10:58-67. RT
69. Mengden T, Vetter H, Tisler A, Illyes M. Tele-monitoring of home blood pressure. Blood Press Monit 2001; 6:185-189.
70. Fagard R, Pardaens K, Staessen J, Thijs L, Amery A. Prognostic value of invasive hemodynamic measurements at rest and during exercise. Hypertension 1996; 26:31-36. OS
71. Mundal R, Kjeldsen SE, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Exercise blood pressure predicts mortality from myocardial infarction. Hypertension 1996; 27:324-329. OS
72. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens 2001; 19:1343-1348. OS
73. Fagard RH, Pardaens K, Staessen JA, Thijs L. Should exercise blood pressure be measured in clinical practice? J Hypertens 1998; 16:1215-1217.
74. Harshfield GA, James GD, Schlussel Y, Yee LS, Blank SG, Pickering TG. Do laboratory tests of blood pressure reactivity predict blood pressure changes during everyday life? Am J Hypertens 1988; 1:168-174. OS
75. Pickering T, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988; 259:225-228. OS
76. Parati G, Ulian L, Santucci C, Omboni S, Mancia G. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 1998; 31:1185-1189.
77. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Task Force V. White-coat hypertension. Blood Press Monit 1999; 4:333-341. GL
78. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, et al. Alterations of cardiac structure in patients with isolated office, ambulatory or home hypertension. Data from the general PAMELA population. Circulation 2001; 104:1385-1392. OS
79. Wing LMH, Brown MA, Beilin LJ, Ryan P, Reid C. Reverse white coat hypertension in older hypertensives. J Hypertens 2002; 20:639-644. OS
80. Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 1999; 131:564-572. OS
81. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-1197. GL
82. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553. GL
83. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793. OS
84. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention for Endpoint Reduction study. J Hypertens 2002; 20:1445-1450. OS
85. Reichek N, Devereux RB, Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981; 63:1391-1398. OS
86. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566. OS
87. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
88. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352. OS
89. Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, Weber KT. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10:657-664.
90. Hoyt RM, Skorton DJ, Collins SM, Melton HE. Ultrasonic backscatter and collagen in normal ventricular myocardium. Circulation 1984; 69:775-782.
91. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93:259-265. OS
92. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2001; 37:1042-1048. OS
93. Working Group Report. How to diagnose diastolic heart failure. European Study on Diastolic Heart Failure. Eur Heart J 1998; 19:990-1003. GL
94. Simon A, Gariepy J, Chironi G, Megnien J-L, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002; 20:159-169. RV
95. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87 (suppl 11):1156-1165. OS
96. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96:1432-1437. OS
97. Hodis HN, Mack WJ, LaBree L, Seizer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-269. OS
98. Zanchetti A, Agabiti Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16:1667-1676. RT
99. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22. OS
100. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422-2427. RT
101. Benetos A, Safar M, Rudnich A, Smulyan H, Richard JL, Ducimetière P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410-1415. OS
102. Safar ME, Frohlich ED. The arterial system in hypertension: a prospective view. Hypertension 1995; 26:10-14. RV
103. Giannattasio C, Mancia G. Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment. J Hypertens 2002; 20:1889-1900. RV
104. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236-1241. OS
105. Pauca AL O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38:932-937.
106. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, London GM. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735-738. OS
107. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
108. Lüscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. BocaRaton, Florida: CRC Press; 1990. RV
109. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002; 20:1671-1674. RV
110. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997; 39:287-324. RV
111. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56:2214-2219. OS
112. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. OS
113. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817-821. OS
114. Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens 1993; 2:962-967. RV
115. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and 2 diabetes. J Intern Med 2003; 254: (in press). RV
116. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20:353-355.
117. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426. OS
118. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K, Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35:898-903. OS
119. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333. OS
120. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782. OS
121. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47-55. RV
122. Ruilope LM, van Veldhuisen DJ, Ritz E, Lüscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001; 38:1782-1787. RV
123. Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G. Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis 2002; 39:1183-1189.
124. Keith NH, Wagener HP, Barker MW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197:332-343. OS
125. Stanton A. Ocular damage in hypertension. In: Zanchetti A, Hansson L, Rodicio JL (editors): Hypertension. London: McGraw-Hill International; 2001, pp. 73-78. RV
126. Minematsu K, Omae T. Detection of damage to the brain. In: Zanchetti A, Hansson L, Rodicio JL (editors): Hypertension. London: McGraw Hill International; 2001, pp. 63-71. RV
127. Price TR, Manolio TA, Kronmal RA, Kittner SJ, Yue NC, Robbins J, et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults: the Cardiovascular Health Study. Stroke 1997; 28:1158-1164. OS
128. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Richard G, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: The ARIC Study. Stroke 1996; 27:2262-2270. OS
129. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145. OS
130. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men. Hypertension 1998; 31:780-786. OS
131. Campos C, Segura J, Rodicio JL. Investigations in secondary hypertension: renal disease. In: Zanchetti A, Hansson L, Rodicio JL (editors): Hypertension. London: McGraw Hill International; 2001, pp. 119-126. RV
132. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33:1004-1010. GL
133. Köler H, Wandel E, Brunck B. Acanthocyturia - a characteristic marker for glomerular bleeding. Kidney Int 1991; 40:115-120. OS
134. Krumme W, Blum U, Schwertfeger E, Flügel P, Höllstin F, Schollmeyer P, Rump LC. Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. Kidney Int 1996; 50:1288-1292. OS
135. Bloch MJ, Pickering TG. Diagnostic strategies in renovascular hypertension. In: Zanchetti A, Hansson L, Rodicio JL (editors): Hypertension. London: McGraw Hill International; 2001, pp. 87-97. RV
136. Vasbinder BGC, Nelemans PJ, Kessels AGH, Kroon AA, De Leeuw PW, van Engelshoven JMA. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001; 135:401-411. MA
137. Fain SB, King BF, Breen JF, Kruger DG, Rieder SJ. High-spatial-resolution contrast-enhanced MR angiography of the renal arteries: a prospective comparison with digital subtraction angiography. Radiology 2001; 218:481-490. OS
138. Bravo EL. Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endocrine Rev 1994; 15:356-368. RV
139. Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992; 152:1193-1197. RV
140. Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339:1828-1834. RV
141. Gordon RD. Diagnostic investigations in primary aldosteronism. In: Zanchetti A, Hansson L, Rodicio JL (editors): Hypertension. London: McGraw Hill International; 2001, pp. 101-114. RV
142. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877-885. OS
143. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High-incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21:315-318. OS
144. Phillips JL, McClellan MW, Pezzullo JC, Rayford W, Choyke PL, Berman AA, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85:4526-4533. OS
145. Orth DN. Cushing's syndrome. N Engl J Med 1995; 332:791-803.
146. Nieman LK. Diagnostic tests for Cushing's syndrome. Ann NY Acad Sci 2002; 970:112-118. RV
147. Luft FC. Molecular genetics of human hypertension. J Hypertens 1998; 16:1871-1878. RV
148. Melander O. Genetic factors of hypertension - what is known and what does it mean? Blood Press 2001; 10:254-270. RV
149. Pausova Z, Tremblay J, Hamet P. Gene-environment interactions in hypertension. Current Hypertens Rep 1999; 1:42-50. RV
150. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
151. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the ephitelial sodium channel. Cell 1994; 79:407-414.
152. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49:757-764.
153. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low renin activity relieved by dexamethasone. Can Med Assoc J 1996; 95:1109-1119.
154. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041. RT
155. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153. RT
156. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int 2002; 61:1086-1097. RT
157. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-1297. OS
158. Hypertension Detection and Follow-up Program. The effect of treatment on mortality in 'mild' hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982; 307:976-980. RT
159. Zanchetti A, Hansson L, Menard J, Leonetti G, Rahn K, Warnold I, Wedel H. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens 2001; 19:819-825. OS
160. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762. RT
161. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS38. BMJ 1998; 317:703-713. RT
162. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin independent diabetes and hypertension. N Engl J Med 1998; 338:645-652. RT
163. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: resurts of prospectively designed overviews of randomised trials. Lancet 2000; 386:1955-1964. MA
164. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al. on behalf of the HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT Study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21:797-804. RT
165. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20:1461-1464. RV
166. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967-1975. RT
167. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997. RT
168. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with
169. Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355:253-259. RT
170. Adler AL, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-429. OS
171. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observational study on male British doctors. BMJ 1994; 309:901-911. OS
172. Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 2001; 37:187-193. OS
173. Omvik P. How smoking affects blood pressure. Blood Press 1996; 5:71-77.
174. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Medical Research Council. BMJ 1985; 291:97-104. RT
175. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3:379-392. RT
176. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343:139-142. MA
177. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. JAMA 2000; 283:3244-3254. GL
178. Tonstad S, Farsang C, Kläne, Lewis K, Manolis A, Perrouhoud AP, et al. Buproprin SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24:947-956. RT
179. Puddey IB, Beilin LJ, Rakie V. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol 1997; 2:159-170. RV
180. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke 1996; 27:1033-1039. OS
181. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1987; 1:647-651. RT
182. Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann Epidemiol 1991; 1:347-362. OS
183. Reid CM, Dart AM, Dewar EM, Jennings GL. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. J Hypertens 1994; 12:291-301. OS
184. Puddey IB, Parker M, Beilin LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992; 20:533-541. OS
185. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of non-pharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839-846. RT
186. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328:533-537. OS
187. Jennings GL. Exercise and blood pressure: Walk, run or swim? J Hypertens 1997; 15:567-569. RV
188. Arakawa K. Antihypertensive mechanism of exercise. J Hypertens 1993; 11:223-229. RV
189. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports and Exerc 2001; 33 (suppl):S484-S492. RV
190. Puddey IB, Cox K. Exercise lowers blood pressure - sometimes? Or did Pheidippides have hypertension? J Hypertens 1995; 13:1229-1233. RV
191. Law MR. Epidemiological evidence on salt and blood pressure. Am J Hypertens 1997; 10 (suppl):42S-45S. RV
192. Cutler JA, Follman D, Alexander PS. Randomised controlled trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65 (suppl 2): 643S-651S. MA
193. Beckmann SL, Os I, Kjeldsen SE, Eide IK, Westheim AS, Hjermann I. Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension. Am J Hypertens 1995; 8:704-711. OS
194. Margetts BM, Beilin LJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomised controlled trial. BMJ 1986; 293:1468-1471. RT
195. Bao DQ, Mori TA, Burke V, Puddey IB, Beilin LJ. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension 1998; 32:710-717. RT
196. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344:3-10. RT
197. Zanchetti A, Mancia G. Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens 1996; 14:809-811.
198. Fagard RH, Staessen JA, Thijs L. Results of intervention trials of antihypertensive treatment versus placebo, no or less intensive treatment. In: Mancia G, Chalmers J, Julius S, Saruta T, Weber M, Ferrari A, Wilkinson I (editors): Manual of hypertension. London: Churchill Livingstone; 2002, pp. 21-33. RV
199. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298. MA
200. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel J-P, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865-872. MA
201. Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10:1103-1109. MA
202. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. The effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Results from a meta-analysis of individual patient data in randomised controlled trials. Ann Intern Med 1997; 126:761-767. MA
203. Lithell H, Hansson L, Skogg I, Elmfeldt D, Hofman A, Olofsson B, et al. for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21; 875-886. RT
204. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869. RT
205. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860. RT
206. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878. RT
207. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, et al. Final outcome results of the Muiticenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276:785-791. RT
208. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34:1129-1133. RT
209. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756. RT
210. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365. RT
211. Agabiti Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A for the VHAS investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997; 15:1337-1344. RT
212. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372. RT
213. Black HR, Elliot WJ, Grandist G, Grambsch P, Lucente T, White WB, et al. for the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003; 289:2073-2082. RT
214. Staessen JA, Wang J, Thijs L. Cardiovascular prevention and blood pressure reduction: a qualitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-1076. MA
215. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720. RT
216. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captoprii Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616. RT
217. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592. RT
218. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. RT
219. Jennings GL, Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In: Hansson L, Birkenhäger WH (editors). Handbook of Hypertension, Vol 18: Assessment of hypertensive organ damage. Amsterdam: Elsevier; 1997, pp. 184-229. MA
220. Schmieder RE, Schlaich MF, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1998). Nephrol Dial Transplant 1998; 13:564-569. MA
221. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg; the LIVE study. J Hypertens 2000; 18:1465-1475. RT
222. Terpstra WL, May JF, Smit AJ, de Graeff PA, Havinga TK, van der Veur E, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19:303-309. RT
223. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104:1248-1254. RT
224. Zanchetti A, Ruilope LM, Cuspidi C, Macca G, Verschuren J, Kerselaers W. Comparative effects of the ACE inhibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of FOAM, a multicenter European study [abstract]. J Hypertens 2001; 19 (suppl 2): S92. RT
225. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, et al. on behalf of the CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20:2293-2300. RT
226. Agabiti Rosei E, Muiesan ML, Trimarco B, Reid J, Salvetti A, Hennig M, Zanchetti A. Changes of LV mass and ABPM during long-term antihypertensive treatment in ELSA [abstract]. J Hypertens 2002; 20 (suppl 4):S4. RT
227. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042. RT
228. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176. RT
229. Dahlöf B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864. RT
230. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001; 103:678-683. OS
231. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793. OS
232. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615-1621. RT
233. Devereux RB, Watchtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou B, et al. Regression of left ventricular hypertrophy: treatment effects and prognostic implications in the LIFE trial [abstract]. J Hypertens 20 (suppl 4):S4. RT
234. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095. OS
235. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54. OS
236. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503-1510. RT
237. Simon A, Gariépy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103:2949-2954. RT
238. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000; 36:438-443. RT
239. Lonn EM, Yusuf S, Dzavik V, Doris Cl, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103:919-925. RT
240. Zanchetti A, Crepaldi G, Bond G, Gallus G, Veglia M, Mancia G. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS) [Abstract]. J Hypertens 2003; 21 (suppl 4):S346.
241. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (suppl 2):B54-B64. RT
242. Lindholm LH, ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010. RT
243. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73-87. MA
244. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002; 288:2421-2431. RT
245. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis. A Randomized Controlled Trial. JAMA 2001; 285:2719-2728. RT
246. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886. RT
247. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202:1028-1034. RT
248. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213:1143-1152. RT
249. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5:93-98. OS
250. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11:1133-1137. OS
251. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup analysis of randomised controlled trials. Lancet 1999; 353:793-796. MA
252. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 16:1237-1245. CT
253. Liu L, Wang JL, Gong L, Liu G, Staessen JA, for the Syst-China Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829. CT
254. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288:1491-1498. RT
255. Fagard RH, Van den Enden M, Leeman M, Wading X. Survey on treatment of hypertension and implementation of WHO-ISH risk stratification in primary care in Belgium. J Hypertens 2002; 20:1297-1302. OS
256. Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Int Med 1999; 159:2004-2009. RT
257. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11:821-827. RV
258. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25 (suppl 1):5-20. GL
259. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diab Med 1997; 14 (suppl 5):S1-S85. OS
260. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-381. RV
261. Haffner SM. The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. J Diabet Complic 1997; 11:69-76. RV
262. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403-418. RV
263. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309-317. OS
264. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17:1247-1251. OS
265. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 128:304-310. RV
266. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27:2033-2039. OS
267. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin- dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418. MA
268. Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11:246-251. OS
269. Dillon JJ. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis 1993; 22:798-802. RV
270. Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22:164-173. RV
271. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481-486.
272. Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Nutr Metab Cardiovasc Dis 2000; 10:287-294. RV
273. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 268:685-688. RT
274. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462. RT
275. PATS Collaborative Group. Post-stroke antihypertensive treatment study. Clin Med J 1995; 108:710-717. RT
276. International Society of Hypertension statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21:665-672. GL
277. Flack JM, Neaton J, Grimm R Jr, Shih J, Cutler J, Ensrud K, MacMahon S. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995; 92:2437-2445. OS
278. Stokes J, Kannel WB, Wolf PA, D'Agostino RB, Cupples LA. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study - 30 years of follow-up. Hypertension 1989; 13 (suppl 1): 113-118. OS
279. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27:335-371. MA
280. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997; 18:560-565. MA
281. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069. RV
282. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450-1456. MA
283. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717. RT
284. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321. RT
285. Zanchetti A. What have we learned and what haven't we from clinical trials on hypertension? In: Laragh JH, Brenner BM (editors): Hypertension, pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press; 1995, pp. 2509-2529. RV
286. McInnes GT. Size isn't everything. ALLHAT in perspective. J Hypertens 2003; 21:459-461.
287. Williams B. Treating hypertension: it is not how you start but where you end that matters. J Hypertens 2003; 21:455-457.
288. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587. RT
289. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675. RT
290. Kaplan NM. The meaning of ALLHAT. J Hypertens 2003; 21:233-234.
291. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine in Survival Evaluation Study Group. N Engl J Med 1996; 335:1107-1114. RT
292. Ruilope LM, Lahera V, Rodicio JL, Romero JC. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994; 23:3-9. RV
293. Perera GA. Hypertensive vascular disease: description and natural history. J Chronic Dis 1955; 1:33-42. OS
294. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124. RT
295. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393. RT
296. Consensus Report: National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 1990; 163:1689-1712. GL
297. Levine RJ, Ewell MG, Hauth JC, Curet LB, Catalano PM, Morris CD, et al. Should the definition of preeclampsia include a rise in diastolic blood pressure of ≥15 mmHg to a level >90 mmHg in association with proteinuria? Am J Obstet Gynecol 2000; 183:787-792. GL
298. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. Can Med Assoc J 1997; 157:715-725. GL
299. Sibai BM, Mabie WC, Shamsa F, Vilnar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162:960-967. RT
300. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol 1998; 105:718-722. RT
301. Moutquin J-M, Garner PR, Burrows RF, Rey E, Helewa ME, Lange IR, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. Can Med Assoc J 1997; 157:907-919. GL
302. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000. MA
303. Olsen S, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Br J Obstet Gynaecol 2000; 107:382-395. MA
304. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents and pre-eclampsia (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford, Update Software, 2000. MA
305. Khedun SM, Moodley J, Naicker T, Maharaj B. Drug management of hypertensive disorders of pregnancy. Pharmacol Ther 1997; 74:221-258. RV
306. de Swiet M. Maternal blood pressure and birthweight. Lancet 2000; 355:81-82.
307. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000; 355:87-92. MA
308. National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. NIH Publication No. 00-3029; originally printed 1990; revised July 2000. GL
309. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of preeclampsia. Lancet 2001; 357:209-215. GL
310. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999; 318:1332-1336. GL
311. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359:1877-1890. RT
312. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063-2070. OS
313. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007. RT
314. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. for the ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003; 361:1149-1158. RT
315. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389. RT
316. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009. RT
317. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357. RT
318. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418. RT
319. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hyprcholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307. RT
320. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622. RT
321. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22. RT
322. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630. RT
323. Prospective studies collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653. MA
324. Crouse JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atheroscterosis 1998; 138:11-24. MA
325. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234. OS
326. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) JAMA 2001; 285:2486-2497. GL
327. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18:220-228. RT
328. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86. MA
329. Zanchetti A, Hansson L, Dahlöf B, Julius S, Menard J, Warnold I, Wedel H. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002; 20:2301-2307. RT
330. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85:265-271. MA
331. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:161-172. MA
332. Diabetes Control and Complications Trial (DCCT). The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45:1289-1298. RT
333. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyorala M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21:360-367. OS
334. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853. RT
335. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986. RT
336. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabetes Med 1999; 16:716-730. GL
337. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360. OS
338. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995; 26:60-69. OS
339. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Human Hypertens 1997; 11:213-220. OS
340. Menotti A, Lanti M, Zanchetti A, Puddu PE, Cirillo M, Mancini M, Vagnarelli OT. Impact of the Gubbio population study on community control of blood pressure and hypertension. Gubbio Study Research Group. J Hypertens 2001; 19:843-850. OS
341. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Can Med Ass J 1995; 153:1423-1431. MA
342. Chalmers J. Implementation of guidelines for management of hypertension. Clin Exper Hypertens 1992; 21:647-657.